Int J Drug Policy:芬太尼,怕上瘾,却又躲不过……

2017-06-09 tianxuexin 来宝网

芬太尼是一种强效的处方阿片类药物,美国罗德艾兰州的吸毒者常用药物。但尽管大家普遍讨厌使用芬太尼,芬太尼目前仍然是导致美国大多数药物过量死亡病例的罪魁祸首。

芬太尼是一种强效的处方阿片类药物,美国罗德艾兰州的吸毒者常用药物。但尽管大家普遍讨厌使用芬太尼,芬太尼目前仍然是导致美国大多数药物过量死亡病例的罪魁祸首。

布朗大学研究小组将这一令人沮丧的研究结果发表在《国际药物政策杂志》上。他们强调打击芬太尼滥用迫在眉睫和颠覆了一种普遍看法,即许多该药的使用者因为其药效而想方设法想弄到它。

“大多数人都不是自己想去找的,”该研究的主要作者,布朗大学Warren Alpert医学院兼职医学助理教授Jennifer Carroll说道,“他们无法抗拒,他们渴望逃避却无法降低他们的风险。”

比对之下可以发现,研究期间罗德艾兰州778例因为药物过量死亡的病例表明,芬太尼相关性死亡发生几乎在海洛因滥用的地区都有发生。芬太尼通常掺在海洛因中一起使用,但许多使用者无法辨别它是否存在于该药物当中。

在整个研究过程中,Carroll及其合着者直接引用了芬太尼使用者的话。Matt,一个20多岁的年轻人,来自罗得岛西部,谈到他对芬太尼的恐惧。

“我看到过使用药物过量的人在我面前射杀无辜,”他引述说。“人们像苍蝇一样纷纷跌落。我有三个发小,从我10岁就玩在一起。他们都死于芬太尼替代海洛因。”

另一位芬太尼使用者Jason说道,如果他因为戒断症状发作而剧烈挣扎的话,他仍然会使用海洛因,即使他怀疑芬太尼的存在。所以他会先尝试一下,看看是否能够感觉得到芬太尼的强效作用。

原始出处:

Brandon D.L. Marshall, Maxwell S. Krieger, et al. Epidemiology of fentanyl-involved drug overdose deaths: A geospatial retrospective study in Rhode Island, USA. International Journal of Drug Policy Available online 7 June 2017 https://doi.org/10.1016/j.drugpo.2017.05.029

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1649662, encodeId=c8021649662f5, content=<a href='/topic/show?id=411d20003f3' target=_blank style='color:#2F92EE;'>#上瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20003, encryptionId=411d20003f3, topicName=上瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6523894616, createdName=wangyang7966, createdTime=Thu Dec 14 23:11:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862249, encodeId=b83d186224915, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Jun 26 10:11:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384802, encodeId=adf81384802f4, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jun 11 04:11:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208622, encodeId=dc922086227a, content=学习了,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 09 15:48:01 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1649662, encodeId=c8021649662f5, content=<a href='/topic/show?id=411d20003f3' target=_blank style='color:#2F92EE;'>#上瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20003, encryptionId=411d20003f3, topicName=上瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6523894616, createdName=wangyang7966, createdTime=Thu Dec 14 23:11:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862249, encodeId=b83d186224915, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Jun 26 10:11:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384802, encodeId=adf81384802f4, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jun 11 04:11:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208622, encodeId=dc922086227a, content=学习了,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 09 15:48:01 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-26 爆笑小医
  3. [GetPortalCommentsPageByObjectIdResponse(id=1649662, encodeId=c8021649662f5, content=<a href='/topic/show?id=411d20003f3' target=_blank style='color:#2F92EE;'>#上瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20003, encryptionId=411d20003f3, topicName=上瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6523894616, createdName=wangyang7966, createdTime=Thu Dec 14 23:11:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862249, encodeId=b83d186224915, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Jun 26 10:11:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384802, encodeId=adf81384802f4, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jun 11 04:11:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208622, encodeId=dc922086227a, content=学习了,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 09 15:48:01 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-11 xue8602
  4. [GetPortalCommentsPageByObjectIdResponse(id=1649662, encodeId=c8021649662f5, content=<a href='/topic/show?id=411d20003f3' target=_blank style='color:#2F92EE;'>#上瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20003, encryptionId=411d20003f3, topicName=上瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6523894616, createdName=wangyang7966, createdTime=Thu Dec 14 23:11:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862249, encodeId=b83d186224915, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Jun 26 10:11:00 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384802, encodeId=adf81384802f4, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jun 11 04:11:00 CST 2017, time=2017-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208622, encodeId=dc922086227a, content=学习了,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 09 15:48:01 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 131****1460

    学习了,受益匪浅。

    0

相关资讯

Yonsei Med J:小儿整形外科术中辅助应用右美托咪定的镇痛的效果优于芬太尼

阿片类药物通常用作局部麻醉剂的硬膜外佐剂,但与潜在的严重副作用(如呼吸抑制)的发生相关。本研究旨在对比右美托咪定与芬太尼作为罗哌卡因硬膜外阻滞在小儿骨科手术中的有效性和安全性。 研究共纳入了60名择期性手术的儿童患者(3 - 12岁),采用患者自控镇痛(PCA)。手术结束前30分钟患者经硬膜外导管接受0.2%罗哌卡因(0.2毫升/公斤)以及右美托咪定(1µg/kg)或芬太尼(1µg/kg)。

FDA批准Ionsys用于急性疼痛管理

美国食品药品监督管理局(FDA)批准离子导入芬太尼透皮贴(Ionsys, The Medicines Co)用于对阿片类止痛剂适用的住院成人患者的术后急性疼痛管理。该系统是一种无针、自控、芬太尼预存给药系统。 “Ionsys是一种传统自控静脉镇痛的新型替代物,具有信用卡般大小的体积,自我粘附设备,采用细微的电流传送所需剂量的芬太尼。”来自